Telix Pharmaceuticals Ltd traded at 10.20 this Monday March 9th, decreasing 0.55 or 5.12 percent since the previous trading session. Looking back, over the last four weeks, Telix Pharmaceuticals lost 1.39 percent. Over the last 12 months, its price fell by 63.15 percent. Looking ahead, we forecast Telix Pharmaceuticals Ltd to be priced at 10.52 by the end of this quarter and at 9.88 in one year, according to Trading Economics global macro models projections and analysts expectations.
Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.